Affiliations: [a] Department of Surgery, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
Correspondence:
[*]
Corresponding author: Prihantono Prihantono, Department of Surgery, Hasanuddin University, Makassar, Indonesia. E-mail: prihantono.md@gmail.com
Abstract: BACKGROUND:AGR2 expression is associated with luminal breast cancer. Overexpression of AGR2 is a predictor of poor prognosis. Several studies have found correlations between AGR2 in disseminated tumor cells (DTCs) in breast cancer patients. OBJECTIVE:This study aims to determine the correlation between anterior Gradient2 (AGR2) expression with the incidence of distant metastases in luminal breast cancer. METHODS:This study was an observational study using a cross-sectional method and was conducted at Wahidin Sudirohusodo Hospital and the network. ELISA methods examine AGR2 expression from blood serum of breast cancer patients. To compare the AGR2 expression in metastatic patients and the non-metastatic patient was tested with Mann Whitney test. The correlation of AGR2 expression and metastasis was tested with the Rank Spearman test. RESULTS:The mean value of AGR2 antibody expression on ELISA in this study was 2.90 ± 1.82 ng/dl, and its cut-off point was 2.1 ng/dl. Based on this cut-off point value, 14 subjects (66.7%) had overexpression of AGR2 serum ELISA, and 7 subjects (33.3%) had not. The mean value AGR2 was significantly higher in metastatic than not metastatic, 3.77 versus 1.76 (p < 0.01). The Spearman rank test obtained a p-value for the 2 tail test of 0.003 (p < 0.05), which showed a significant correlation of both, while the correlation coefficient of 0.612 showed a strong positive correlation of AGR2 overexpression and metastasis. CONCLUSIONS:AGR2 expression is correlated with metastasis in Luminal breast cancer.
Keywords: Breast cancer, luminal, AGR2, ELISA, serum, metastasis
DOI: 10.3233/BD-219015
Journal: Breast Disease, vol. 40, no. s1, pp. S103-S107, 2021
